Rezolute, Inc.

What they do

Rezolute is a late-stage rare disease company focused on developing therapies for hyperinsulinism (HI), a condition of excessive insulin production causing hypoglycemia. Its lead asset, ersodetug, is an intravenously administered human monoclonal antibody that down-modulates insulin receptor signaling to counteract elevated insulin and restore glucose levels. The company is developing ersodetug for congenital HI and tumor HI, with two Phase 3 studies: sunRIZE (completed enrollment, topline announced) and upLIFT (enrolling).

Revenue drivers

• Ersodetug for congenital HI — Primary potential revenue source; no approved product yet. U.S. addressable market estimated at more than 1,500 individuals for congenital HI.
• Ersodetug for tumor HI — Registrational Phase 3 upLIFT study; target of as few as 16 patients; topline expected in second half 2026.
• Rare pediatric disease priority review voucher — Eligible for a voucher upon BLA submission if approved; could provide non-dilutive funding.

Recent performance

For the quarter ended March 31, 2026, Rezolute reported a net loss of $16.2 million. Cash and investments were $120.3 million as of March 31, 2026, down from $167.9 million as of June 30, 2025. The Phase 3 sunRIZE study did not meet its primary or key secondary endpoints in December 2025, though CGM-based analyses presented in May 2026 showed nominally statistically significant improvements compared to placebo.

Strategy

Management is focused on gaining FDA alignment on the regulatory path for ersodetug in congenital HI after the sunRIZE miss, and on completing the Phase 3 upLIFT study in tumor HI. They plan to submit comprehensive data to the FDA as encouraged, and may pursue a BLA for ersodetug if supportive data are achieved. The company also hired a Chief Commercial Officer in August 2025 to prepare for potential commercialization.

Risks

• Phase 3 miss for congenital HI — sunRIZE failed its primary and key secondary endpoints, creating significant regulatory and commercial uncertainty.
• Regulatory approval challenges — FDA reiterated the need for adequate and well-controlled studies, and the company must convince the agency of ersodetug's efficacy based on post-hoc analyses.
• Cash burn rate — Net losses and operating cash outflows have been increasing annually (net loss of $74.4M in FY2025), and cash declined by $47.6M in the first three quarters of FY2026.
• Clinical trial risks for tumor HI — The upLIFT study is small and open-label, and topline results due in H2 2026 may not be supportive.

Outlook

Management expects to report topline data for upLIFT in the second half of 2026. For congenital HI, they are working with the FDA following the March 2026 Type B meeting to determine the path forward, with FDA encouraging submission of comprehensive datasets. The company anticipates providing a program update in H2 2026.